GRAL
GRAIL, Inc. NASDAQ Listed Jun 12, 2024$63.40
After hrs
$65.18
+2.81%
Mkt Cap $2.7B
52w Low $29.95
37.6% of range
52w High $118.84
50d MA $66.88
200d MA $74.25
P/E (TTM)
—
EV/EBITDA
—
P/B
1.0x
Debt/Equity
0.0x
ROE
-15.8%
P/FCF
-10.2x
RSI (14)
53.30
ATR (14)
$4.06
Beta
4.64
50d MA
$66.88
200d MA
$74.25
Avg Volume
540.9K
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
1525 O'BRIEN DRIVE · MENLO PARK, CA 94025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | AMC | -2.66 | -2.56 | +3.8% | — | — | — | — | — | — | — | — |
| May 5, 2026 | AMC | -2.76 | -2.29 | +17.1% | 54.40 | +2.9% | +15.3% | +0.3% | -2.0% | -0.6% | +1.2% | — |
| Feb 19, 2026 | AMC | -3.33 | -2.44 | +26.7% | 101.53 | -51.1% | -50.5% | -14.3% | +17.0% | +2.9% | +12.2% | — |
| Nov 12, 2025 | AMC | -3.36 | -2.46 | +26.8% | 84.77 | +1.6% | -1.9% | -4.3% | +6.7% | -4.1% | +8.0% | — |
| Aug 12, 2025 | AMC | -3.14 | -3.18 | -1.3% | 33.60 | -3.2% | +1.1% | -5.3% | +0.8% | +1.1% | -4.2% | — |
| May 13, 2025 | AMC | -4.03 | -3.10 | +23.1% | 42.89 | -12.8% | -23.3% | +18.5% | +2.4% | -4.2% | +2.9% | — |
| Feb 20, 2025 | AMC | -4.41 | -1.86 | +57.8% | 47.76 | +2.6% | -14.7% | +11.2% | -4.8% | +1.8% | -10.5% | — |
| Nov 12, 2024 | AMC | -6.43 | -3.94 | +38.7% | 15.09 | -1.6% | +5.5% | -0.7% | -6.4% | -5.4% | +5.6% | — |
| Aug 13, 2024 | AMC | — | -5.30 | — | 15.84 | +12.8% | -2.8% | +3.1% | +5.5% | +0.2% | -4.3% | — |
| Mar 31, 2024 | AMC | — | -7.05 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.18 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -28.71 | — | — | — | — | — | — | — | — | — |
| Jun 29, 2023 | AMC | — | -6.22 | — | — | — | — | — | — | — | — | — |
| Apr 2, 2023 | AMC | — | -6.24 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 5 | Goldman | Initiates | Neutral | $60 | $66.55 | $63.99 | -3.8% | -9.9% | +2.6% | -1.0% | -3.8% | +2.7% |
| Jun 2 | Wolfe Research | Reiterates | Peer Perform | — | $64.40 | $64.00 | -0.6% | -7.0% | +2.1% | +8.9% | -9.9% | +2.6% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $48.49 | $49.00 | +1.1% | -3.3% | +10.2% | +3.7% | +2.6% | -5.9% |
| Feb 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $43.03 | $42.71 | -0.7% | +17.0% | +2.9% | +12.2% | -8.4% | -1.1% |
| Feb 20 | Baird | Maintains | Outperform → Outperform | — | $101.53 | $49.66 | -51.1% | -50.5% | -14.3% | +17.0% | +2.9% | +12.2% |
| Feb 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $101.53 | $49.66 | -51.1% | -50.5% | -14.3% | +17.0% | +2.9% | +12.2% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $104.90 | $104.51 | -0.4% | +1.3% | +2.5% | -7.3% | -0.0% | -3.1% |
| Dec 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $98.27 | $99.44 | +1.2% | -0.9% | +3.9% | +3.5% | -3.6% | -1.2% |
| Nov 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $79.63 | $79.20 | -0.5% | +6.7% | -4.1% | +8.0% | -2.6% | +9.2% |
| Nov 12 | Guggenheim | Upgrade | Neutral → Buy | — | $83.39 | $88.57 | +6.2% | +1.7% | -1.9% | -4.3% | +6.7% | -4.1% |
| Oct 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $83.71 | $83.89 | +0.2% | -4.7% | +3.6% | +8.2% | -4.9% | +1.6% |
| Oct 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $64.73 | $67.00 | +3.5% | +1.3% | -5.9% | +1.8% | +15.9% | -2.3% |
| May 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $42.89 | $37.40 | -12.8% | -23.3% | +18.5% | +2.4% | -4.2% | +2.9% |
| Mar 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $29.13 | $29.19 | +0.2% | -3.3% | -0.6% | -0.7% | +8.9% | +6.1% |
No insider trades available.
8-K
GRAIL, Inc. -- 8-K Filing
I cannot write a meaningful analysis sentence from this filing summary, as it contains only standard SEC procedural language without substantive information about GRAIL's business developments or financial events.
Jun 22
8-K · 5.02
!!! Very High
GRAIL, Inc. -- 8-K 5.02: Executive Change
Dr. Joshua Ofman's resignation as director of GRAIL, Inc. reduces board oversight capacity and may signal internal disagreements or strategic shifts at the cancer diagnostics company.
Jun 1
8-K · 2.02
!! High
GRAIL, Inc. -- 8-K 2.02: Earnings Results
GRAIL reported Q1 2026 financial results, providing investors with updates on operational performance and financial condition through March 31, 2026.
May 5
8-K · 8.01
!! High
GRAIL, Inc. -- 8-K 8.01: Material Event / Announcement
GRAIL issued a press release announcing material developments, with management and expert commentary that the company explicitly excludes from SEC filing incorporation, signaling investors should review the full announcement for details.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 3,023,374 | $259M | Added | Dec 2025 |
| 2 | Farallon Capital Management Llc | 3,253,684 | $168M | New | Mar 2026 |
| 3 | Primecap Management Co/ca/ | 1,843,772 | $95M | — | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 1,527,105 | $79M | New | Mar 2026 |
| 5 | Arbiter Partners Capital Management Llc | 1,034,597 | $53M | — | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 914,114 | $47M | Added | Mar 2026 |
| 7 | Alyeska Investment Group, L.p. | 645,456 | $33M | Added | Mar 2026 |
| 8 | Northern Trust Corp | 349,137 | $18M | Added | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 334,906 | $17M | New | Mar 2026 |
| 10 | Susquehanna International Group, Llp | 304,808 | $16M | Added | Mar 2026 |
| 11 | Raymond James Financial Inc | 292,138 | $15M | Added | Mar 2026 |
| 12 | Aqr Capital Management Llc | 292,004 | $15M | Reduced | Mar 2026 |
| 13 | Braidwell Lp | 142,755 | $12M | New | Dec 2025 |
| 14 | Carnegie Investment Counsel | 217,100 | $11M | Added | Mar 2026 |
| 15 | Natixis | 199,368 | $10M | New | Mar 2026 |
| 16 | Reynders Mcveigh Capital Management, Llc | 112,869 | $10M | Reduced | Dec 2025 |
| 17 | Ubs Group Ag | 185,393 | $10M | Reduced | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 148,775 | $8M | Added | Mar 2026 |
| 19 | Franklin Resources Inc | 147,985 | $8M | Added | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 133,914 | $7M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.72B
Enterprise Value
$2.84B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.09x
P/B
1.01x
P/S
15.74x
P/FCF
-10.18x
EV/EBITDA
—
Shares Out
41.0M
Financials (TTM)
Revenue
$165.3M
Net Income
-$391.6M
EBITDA
-$412.8M
Free Cash Flow
-$299.0M
Op Cash Flow
-$299.0M
EPS Basic
$-11.11
EPS Diluted
$-9.75
EPS Forward
$-11.08
Gross Margin
-10.8%
Op Margin
-338.4%
Net Margin
-236.9%
Balance Sheet
Total Assets
$2.92B
Total Liab.
$344.2M
Total Equity
$2.58B
Cash
$249.7M
LT Debt
$43.1M
Book Value/Sh
$62.84
Debt/Equity
0.04x
Current Ratio
11.97
Quick Ratio
11.77
Returns & Growth
ROE
-15.8%
ROA
-14.0%
ROIC
-14.3%
Rev Growth YoY
+17.2%
EPS Growth YoY
+82.5%
Price Returns
2W
+5.0%
1M
+7.6%
3M
+18.2%
6M
-25.9%
12M
+124.2%
Technicals
52W High
$118.84
52W Low
$29.95
50d MA
$66.88
200d MA
$74.25
RSI (14)
53.30
ATR (14)
$4.06
Beta
4.64
Avg Volume
541K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$77.33
High
$130.00
Low
$54.00
Median
$70.00
Data updated apr 25, 2026 12:13pm
· Source: financialmodelingprep.com